Cascara Sagrada

Cascara sagrada is a plant laxative whose therapeutic value, according to Ray Peat, depends entirely on proper aging to eliminate its irritant properties. 2 When unaged, it causes overstimulation, irritation, and cramping, but when aged to a color darker than chocolate, it becomes anti-inflammatory and sedative, increasing water secretion into the intestine to soften stool without the purging effect. 2 Peat emphasized that the taste itself is important for its action, and that individual sensitivity varies enormously, with a mere taste capable of stimulating the entire digestive system. 5

The primary active constituent is emodin, an anthraquinone that Peat identified as structurally analogous to vitamin K, coenzyme Q10, and tetracycline, sharing their anti-inflammatory, anti-cancer, and anti-stress properties. 2 Peat’s research interest in emodin originated from his graduate work on oxidative metabolism, where he found that colored plant compounds could simulate mitochondrial respiration. 4 He described emodin as reinforcing all of the body’s own defense systems, increasing energy production the way thyroid and progesterone do, while specifically blocking the coronavirus spike protein and the angiotensin-converting enzyme. 2 Its anti-cancer mechanisms include lowering hypoxia inducible factor 1 alpha (HIF-1α) and attenuating the expression of collagenase enzymes involved in metastasis, as well as a more fundamental epigenetic reprogramming through demethylation and inhibition of histone deacetylase enzymes. 2

Peat detailed a regulatory history in which the FDA removed cascara from the market as a laxative by labeling it a potential carcinogen, a move he argued was timed to clear the market for the synthetic drug Zelnorm. 3 Zelnorm acted by intensifying serotonin signaling to force bowel movements, but this spastic stimulation chronically deprived the intestine of oxygen, leading to colon death and necessitating surgical removal in many patients before the drug itself was withdrawn. 3 Peat noted that the pharmaceutical industry was simultaneously investigating emodin as a promising cancer treatment, and that the carcinogen accusation was never supported by research but was instead part of a campaign against natural substances. 3 He also clarified that the brown pigmented colon sometimes observed in laxative users was actually caused by the underlying constipation and irritation, not by the proper use of cascara. 9

Peat considered cascara a tool for reducing inflammation and constipation while identifying and correcting the underlying cause, which he most often attributed to hypothyroidism slowing all digestive secretions and peristalsis. 9 He stated that people have taken it daily for decades without harm, and that in serious conditions like advanced kidney failure, its restorative effects on mitochondrial respiration and kidney function far outweigh any concern about its laxative action. 2 He recommended a typical tablet size of 500 mg, but noted that even a quarter of that was excessive for many, and that the laxative effect usually takes about eight hours. 5